New York, May 20, 2026, 17:07 EDT
- CG Oncology shares were last quoted at $64.76, up 2.3%, with a market value of about $5.47 billion.
- Wolfe Research began coverage with a Peer Perform rating, a broadly neutral call, as it flagged launch and adoption questions around cretostimogene.
- The next big stock driver remains clinical: CG Oncology expects PIVOT-006 Phase 3 top-line data in the first half of 2026 and completion of its first biologics license application in the fourth quarter.
Shares of CG Oncology rose on Wednesday, helped by a firmer U.S. tape and a market still trying to price the next data readout for its experimental bladder-cancer therapy, cretostimogene grenadenorepvec. The stock was last quoted at $64.76, up 2.3%, with volume near 768,000 shares.
Why now is simple enough. CG Oncology is no longer just a small biotech with a long runway; its shares are trading around a near-term trial readout, a planned regulatory filing and early Wall Street debate over how fast the drug could sell if approved. A biologics license application, or BLA, is the main U.S. filing needed for approval of a biologic medicine.
The company’s lead drug is aimed at non-muscle invasive bladder cancer, or NMIBC, a form of bladder cancer that has not grown into the bladder muscle. Cretostimogene is given into the bladder, a route known as intravesical delivery, and is an oncolytic immunotherapy, meaning it is designed to attack cancer cells and trigger an immune response. CG Oncology says the drug remains investigational and has not been approved by the FDA or any other health authority.
Wolfe Research analyst Kalpit Patel initiated coverage of CG Oncology with a Peer Perform rating on May 19, according to StreetInsider. A separate summary of the note said Wolfe sees key catalysts from PIVOT-006 and a possible approval in BCG-unresponsive NMIBC, but remains cautious on early commercial uptake and use in intermediate-risk disease. BCG is an older immune-based bladder-cancer treatment; “BCG-unresponsive” means the disease no longer responds adequately to it. Streetinsider
That caution lands a few days after CG Oncology reported first results from CORE-008 Cohort CX, a Phase 2 study of cretostimogene with gemcitabine. The company said high-grade event-free survival — no high-grade recurrence, progression or death — was 96.0% at three months and 89.5% at six months, while complete response rates in patients with carcinoma in situ were 85.7% and 92.3% in two analysis groups.
CG Oncology Chief Medical Officer Vijay Kasturi said the early data showed “robust clinical activity” and a “favorable safety profile.” Trinity Bivalacqua, the University of Pennsylvania urologist leading the cohort, said the study showed consistent responses across BCG-exposed and BCG-unresponsive patients. CG Oncology
The company has also told investors it has completed the clinical and non-clinical modules for its first BLA. Chief Executive Arthur Kuan said the remaining manufacturing-related module is moving ahead and that CG Oncology is “on track to finalize” the submission in the fourth quarter of 2026. CG Oncology
Competition is not theoretical. Johnson & Johnson’s Inlexzo, formerly TAR-200, won FDA approval in September 2025 for adults with BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors. FDA data for Inlexzo showed an 82% complete response rate, and 51% of responding patients had a response lasting at least 12 months.
But the setup leaves little margin for a miss. Cretostimogene is still unapproved, interim trial results can change with more follow-up, and Wolfe’s caution points to a harder commercial path if Johnson & Johnson’s Inlexzo gains deeper footing in urology practices before CG Oncology reaches market. A delayed BLA, weaker PIVOT-006 data, or slower-than-expected adoption would likely test the stock’s recent strength.
The broader tape helped. Wall Street’s main indexes closed more than 1% higher on Wednesday, with technology and chip stocks leading before Nvidia’s results. BMO Private Wealth strategist Carol Schleif told Reuters that “Technology is driving the bus,” a backdrop that gave growth and biotech shares a cleaner bid than they had earlier in the week. Reuters
CG Oncology’s latest company announcement, dated May 19, was not a trial or regulatory update. It named Patrick Hensley of the University of Kentucky Research Foundation and Daniel Joyce of Vanderbilt University Medical Center as recipients of NMIBC research fellowship grants of up to $50,000 each.
For the stock, the next hard turn still looks clinical. Investors have the broad timeline, the first combination data, and now a neutral Wolfe start to coverage. What they do not yet have is the PIVOT-006 result that could decide whether Wednesday’s move was just a bounce, or part of a larger re-rating.
